NCT06846281 - Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Biotech Hunter

Enrollment

360

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

February 7, 2030

Study Completion Date

January 8, 2032

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG

Remibrutinib oral treatment

Remibrutinib tablet taken daily

DRUG

Ocrelizumab

Ocrelizumab 600mg infusion or 920mg injection

Trial Locations (6)

RECRUITING

Novartis Investigative Site, St Leonards

RECRUITING

Novartis Investigative Site, Liverpool

RECRUITING

Novartis Investigative Site, Melbourne

RECRUITING

Novartis Investigative Site, Parkville

RECRUITING

Novartis Investigative Site, Cape Town

RECRUITING

Novartis Investigative Site, Lévis